KRBP
Income statement / Annual
Last year (2023), Kiromic BioPharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Kiromic BioPharma, Inc.'s net income was -$21.29 M.
See Kiromic BioPharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$2.80 M |
$2.07 M |
$469,800.00 |
$200,000.00 |
$87,500.00 |
$80,900.00 |
| Gross Profit |
-$2.80 M |
-$2.07 M |
-$469,800.00 |
-$200,000.00 |
-$87,500.00 |
-$80,900.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$9.62 M
|
$13.92 M
|
$11.37 M
|
$5.05 M
|
$1.20 M
|
$1.42 M
|
| General & Administrative
Expenses |
$10.31 M
|
$17.19 M
|
$13.94 M
|
$14.14 M
|
$2.50 M
|
$1.76 M
|
| Selling & Marketing
Expenses |
-$2.80 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$7.52 M
|
$17.19 M
|
$13.94 M
|
$14.14 M
|
$2.50 M
|
$1.76 M
|
| Other Expenses |
$0.00 |
$0.00 |
$53,400.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$19.94 M |
$31.11 M |
$25.31 M |
$19.20 M |
$3.71 M |
$3.18 M |
| Cost And Expenses |
$19.94 M |
$31.11 M |
$25.31 M |
$19.20 M |
$3.71 M |
$3.18 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
-$1.85 M |
$166,500.00 |
$12,200.00 |
$3,300.00 |
$22,500.00 |
$633,100.00 |
| Depreciation &
Amortization |
$2.80 M
|
$2.07 M
|
$469,800.00
|
$200,000.00
|
$87,500.00
|
$80,900.00
|
| EBITDA |
-$16.30 M
|
-$32.50 M
|
-$25.74 M
|
-$19.00 M
|
-$3.62 M
|
-$3.10 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$1.01 M
|
-$3.62 M
|
$147,000.00
|
-$3,300.00
|
-$22,500.00
|
-$633,100.00
|
| Income Before Tax |
-$20.95 M |
-$34.73 M |
-$25.59 M |
-$19.20 M |
-$3.73 M |
-$3.82 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$3.45 M |
$65,600.00 |
$3,300.00 |
$22,500.00 |
-$80,241.00 |
| Net Income |
-$21.29 M |
-$38.18 M |
-$25.65 M |
-$19.20 M |
-$3.75 M |
-$3.82 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-21.41 |
-70.12 |
-67.4 |
-79.08 |
-29 |
-32.4 |
| EPS Diluted |
-21.41 |
-70.12 |
-67.4 |
-79.08 |
-29 |
-32.4 |
| Weighted Average Shares
Out |
$1.10 M
|
$544,529.00
|
$380,607.00
|
$242,831.00
|
$129,323.00
|
$117,763.00
|
| Weighted Average Shares
Out Diluted |
$1.10 M
|
$544,529.00
|
$380,607.00
|
$242,831.00
|
$129,323.00
|
$117,763.00
|
| Link |
|
|
|
|
|
|
